A carregar...
Randomised, double-blind, placebo-controlled trial with azithromycin selects for anti-inflammatory microbial metabolites in the emphysematous lung
INTRODUCTION: Azithromycin (AZM) reduces pulmonary inflammation and exacerbations in patients with COPD having emphysema. The antimicrobial effects of AZM on the lower airway microbiome are not known and may contribute to its beneficial effects. Here we tested whether AZM treatment affects the lung...
Na minha lista:
| Publicado no: | Thorax |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5329050/ https://ncbi.nlm.nih.gov/pubmed/27486204 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/thoraxjnl-2016-208599 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|